Stock Events

Stock Events

Climb Bio 

$12.70
40
+$0.12+0.95% Friday 20:00
+$0.00+0%Friday 23:03After hours

Statistics

Day High
12.74
Day Low
12.68
52W High
14.42
52W Low
1.36
Volume
28,686
Avg. Volume
-
Mkt Cap
727.24M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.31
-0.25
-0.19
-0.13
Expected EPS
-0.210414
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
2025
0Revenue
-59.85MNet Income

Analyst Ratings

20.64Average Price Target
The highest estimate is 35.00.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLYM. It's not an investment recommendation.
NVIDIA
4
NVDA
Bitcoin
3
BTC.CRYPTO
AMD
3
AMD
Crowdstrike
3
CRWD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap29.4B
Biogen has a strong focus on neurological diseases, making it a direct competitor in the neurology space.
Alkermes
ALKS
Mkt Cap8.66B
Alkermes works on central nervous system (CNS) diseases, overlapping with Eliem's focus areas.
Acadia Pharmaceuticals
ACAD
Mkt Cap4.49B
Acadia Pharmaceuticals specializes in CNS disorders, including treatments for neurological and psychiatric conditions.
AMGEN
AMGN
Mkt Cap196.12B
Amgen has a broad portfolio that includes treatments for neurological conditions, competing in the same therapeutic area.
Novartis
NVS
Mkt Cap293.94B
Novartis offers a wide range of neurology and psychiatry medications, making it a competitor in Eliem's market.
Pfizer
PFE
Mkt Cap137.76B
Pfizer has a diversified portfolio that includes drugs for neurological conditions, directly competing with Eliem.
Lilly(Eli) &
LLY
Mkt Cap1.06T
Eli Lilly has a strong emphasis on neurodegenerative diseases and psychiatric disorders, areas of interest for Eliem.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap38.37B
Teva Pharmaceutical Industries has a focus on CNS treatments, including generic and specialty medicines that compete with Eliem.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson, through its pharmaceutical segment Janssen, develops treatments for neurological and mental health conditions, competing with Eliem.

About

Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Show more...
CEO
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
Employees
29
Country
United States
ISIN
US28658R1068

Listings

BOATS
BOATS
CLYM.BOATS
XNAS
US
CLYM

0 Comments

Share your thoughts

FAQ

What is Climb Bio stock price today?▼
The current price of CLYM is $12.70 USD — it has increased by +0.95% in the past 24 hours. Watch Climb Bio stock price performance more closely on the chart.
What is Climb Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Climb Bio stocks are traded under the ticker CLYM.
Is Climb Bio stock price growing?▼
CLYM stock has fallen by -9.29% compared to the previous week, the month change is a +10.92% rise, over the last year Climb Bio has showed a +741.06% increase.
What is Climb Bio market cap?▼
Today Climb Bio has the market capitalization of 727.24M
When is the next Climb Bio earnings date?▼
Climb Bio is going to release the next earnings report on August 18, 2026.
What were Climb Bio earnings last quarter?▼
CLYM earnings for the last quarter are -0.2 USD per share, whereas the estimation was -0.29 USD resulting in a +30.54% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Climb Bio revenue for the last year?▼
Climb Bio revenue for the last year amounts to 0 USD.
What is Climb Bio net income for the last year?▼
CLYM net income for the last year is -59.85M USD.
How many employees does Climb Bio have?▼
As of July 18, 2026, the company has 29 employees.
In which sector is Climb Bio located?▼
Climb Bio operates in the Health & Wellness sector.
When did Climb Bio complete a stock split?▼
Climb Bio has not had any recent stock splits.
Where is Climb Bio headquartered?▼
Climb Bio is headquartered in Wellesley Hills, United States.